Combination biologic treatment of refractory psoriasis and psoriatic arthritis

Journal of Rheumatology

Volumn 39, Issue 1, 2012, Pages 187-193

  Cuchacovich, Raquel ^a   Garcia Valladares, Ignacio ^a   Espinoza, Luis R ^a  

^a LOUISIANA STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABATACEPT; ADALIMUMAB; BIOLOGICAL PRODUCT; CORTICOSTEROID DERIVATIVE; ETANERCEPT; HLA B27 ANTIGEN; INFLIXIMAB; METHOTREXATE; SALAZOSULFAPYRIDINE; USTEKINUMAB;

ABSENCE OF SIDE EFFECTS; ADULT; BIOLOGICAL THERAPY; CASE REPORT; CLINICAL ASSESSMENT; DAILY LIFE ACTIVITY; DISEASE DURATION; ENTHESITIS; FOLLOW UP; HUMAN; LETTER; MALE; MONOTHERAPY; PHOTOTHERAPY; PRIORITY JOURNAL; PSORIASIS; PSORIASIS AREA AND SEVERITY INDEX; PSORIATIC ARTHRITIS; SYNOVITIS; TREATMENT OUTCOME;

ADULT; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, PSORIATIC; BIOLOGICAL AGENTS; DRUG THERAPY, COMBINATION; HUMANS; IMMUNOGLOBULIN G; MALE; PSORIASIS; RECEPTORS, TUMOR NECROSIS FACTOR; TREATMENT OUTCOME;

EID: 84855385526     PISSN: 0315162X     EISSN: 14992752     Source Type: Journal    
DOI: 10.3899/jrheum.110295     Document Type: Letter

References (32)

1. Annunziato F, Cosmi L, Liotta F, Maggi E, Romagnani S. Type 17 helper cells - origins, features and possible roles in rheumatic diseases. Nat Rev Rheumatol 2009;5:325-31.
2. Nestle FO, Kaplan DH, Barker J. Psoriasis. N Engl J Med 2009;361:496-509.
3. Garcia-Valladares I, Espinoza LR. Psoriasis pathophysiology. Immunotherapy 2010;2:444-5.
4. Chang CJ, Chen YH, Huang KW, Cheng HW, Chan SF, Tai KF, et al. Combined GM-CSF and IL-12 gene therapy synergistically suppresses the growth of orthotopic liver tumors. Hepatology 2007;45:746-54.
5. Perez-Gracia JL, Berraondo P, Martinez-Forero I, Alfaro C, Suarez N, Gurpide A, et al. Clinical development of combination strategies in immunotherapy: are we ready for more than one investigational product in an early clinical trial? Immunotherapy 2009;1:845-53.
6. Huang KW, Wu HL, Lin HL, Liang PC, Chen PJ, Chen SH, et al. Combining antiangiogenic therapy with immunotherapy exerts better therapeutical effects on large tumors in a woodchuck hepatoma model. Proc Natl Acad Sci USA 2010;107:14769-74.
7. Mihara K, Yanagihara K, Takigahira M, Kitanaka A, Imai C, Bhattacharyya J, et al. Synergistic and persistent effect of T-cell immunotherapy with anti-CD19 or anti-CD38 chimeric receptor in conjunction with rituximab on B-cell non-Hodgkin lymphoma. Br J Haematol 2010;151:37-46.
8. Yarden Y. The biological framework: translational research from bench to clinic. Oncologist 2011;16:23-9.
9. Greenwald MW, Shery WJ, Kaine JL, Sweetser MT, Gilder K, Linnik MD. Evaluation of the safety of rituximab in combination with a tumor necrosis factor inhibitor and methotrexate in patients with active rheumatoid arthritis: Results from a randomized controlled trial. Arthritis Rheum 2001;63:622-32.
10. Genovese MC, Cohen S, Moreland L, Lium D, Robbins S, Newmark R, et al. Combination therapy with etanercept and anakinra in the treatment of patients with rheumatoid arthritis who have been treated unsuccessfully with methotrexate. Arthritis Rheum 2004;50:1412-9. (Pubitemid 38608062)
11. Bendele AM, Chlipala ES, Scherrer J, Frazier J, Sennello G, Rich WJ, et al. Combination benefit of treatment with the cytokine inhibitors interleukin-1 receptor antagonist and PEGylated soluble tumor necrosis factor receptor type I in animal models of rheumatoid arthritis. Arthritis Rheum 2000;43:2648-59. (Pubitemid 32001730)
12. Feige U, Hu YL, Gasser J, Campagnuolo G, Munyakazi L, Bolon B. Anti-interleukin-1 and anti-tumor necrosis factor-a synergistically inhibit adjuvant arthritis in Lewis rats. Cell Mol Life Sci 2000;57:1457-70.
13. Weinblatt M, Schiff M, Goldman A, Kremer J, Luggen M, Li T, et al. Selective costimulation modulation using abatacept in patients with active rheumatoid arthritis while receiving etanercept: a randomised clinical trial. Ann Rheum Dis 2007;66:228-34. (Pubitemid 46226059)
14. Record JL, Beukelman T, Cron RQ. Combination therapy of abatacept and anakinra in children with refractory systemic juvenile idiopathic arthritis: a retrospective case series. J Rheumatol 2011;38:180-1.
15. Ritchlin CT, Kavanaugh A, Gladman DD, Mease PJ, Helliwell P, Boehncke WH, et al. Treatment recommendations for psoriatic arthritis. Ann Rheum Dis 2009;68:1387-94.
16. Menter A, Korman NJ, Elmets CA, Feldman SR, Gelfand JM, Gordon KB, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 4. Guidelines of care for the management and treatment of psoriasis with traditional agents. J Am Acad Dermatol 2009;61:451-85.
17. Matthews JB, Staeva TP, Bernstein PL, Peakman M, von Herrath M; ITN-JDRF Type 1 Diabetes Combination Therapy Assessment Group. Developing combination immunotherapies for type 1 diabetes: recommendations from the ITN-JDRF Type 1 diabetes combination therapy assessment group. Clin Exp Immunol 2010;160:176-84.
18. Lowes MA, Turton JA, Krueger JG, Barnetson RS. Psoriasis vulgaris flare during efalizumab therapy does not preclude future use: a case series. BMC Dermatol 2005;18:5-9.
19. Adisen E, Karaca F, Gürer MA. When there is no single best biological agent: psoriasis and psoriatic arthritis in the same patient responding to different biological agents. Clin Exp Dermatol 2008;33:164-6. (Pubitemid 351197223)
20. Hamilton TK. Treatment of psoriatic arthritis and recalcitrant skin disease with combination therapy. J Drugs Dermatol 2008;7:1089-93.
21. Kitamura G, Mehr N, Anderson N, Sirichotiratana M. A case of tuberculosis in a patient on efalizumab and etanercept for treatment of refractory palmopustular psoriasis and psoriatic arthritis. Dermatol Online J 2009;15:11.
22. Mease P, Genovese MC, Gladstein G, Kivitz AJ, Ritchlin C, Tak PP, et al. Abatacept in the treatment of patients with psoriatic arthritis: results of a six-month, multicenter, randomized, double blind, placebo-controlled, phase II trial. Arthritis Rheum 2011;63:939-48.
23. Glintborg B, Ostergaard M, Dreyer L, Krogh NS, Tarp U, Hansen MS, et al. Treatment response, drug survival, and predictors thereof in 764 patients with psoriatic arthritis treated with anti tumor necrosis factor a therapy: results from the nationwide Danish DANBIO registry. Arthritis Rheum 2011;63:382-90.
24. van de Kerkhof PC. Novel biologic therapies in development targeting IL-12/IL-23. J Eur Acad Dermatol Venereol 2010;24 Suppl 6:5-9.
25. Garcia-Valladares I, Cuchacovich R, Espinoza LR. Comparative assessment of biologics in treatment of psoriasis: drug design and clinical effectiveness of ustekinumab. Drug Des Devel Ther 2011;5:41-9.
26. Reddy M, Torres G, McCormick T, Marano C, Cooper K, Yeilding N, et al. Positive treatment effects of ustekinumab in psoriasis: Analysis of lesional and systemic parameters. J Dermatol 2010;33:413-25.
27. Griffiths CE, Strober BE, van de Kerkhof P, Ho V, Fidelus-Gort R, Yeilding N, et al. Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis. N Engl J Med 2010;362:118-28.
28. Cuchacovich R, Espinoza LR. Ustekinumab for psoriatic arthritis. Lancet 2009;373:605-6.
29. Necas M, Vasku V. Ustekinumab in the treatment of severe rupioid psoriasis: A case report. Acta Dermatovenerol Alp Panonica Adriat 2010;19:23-7.
30. Ait-Oufella H, Herbin O, Bouaziz JD, Binder C, Mallet Z. B-cell depletion reduces the development of atherosclerosis in mice. J Exp Med 2010;207:1579-87.
31. Langley R, Papp K, Gottlieb A, Krueger G, Strober B, Williams D, et al. Long-term safety and efficacy of ABT-874 for the treatment of moderate to severe psoriasis - Interim analysis from an open-label extension study. [Internet. Accessed Aug 8, 2011.] Available from: http://www.dermatology.ca/conference/ 2010/2010Abstracts.pdf
32. Reich K, Langley RG, Lebwohl M, Szapary P, Guzzo C, Yeilding N, et al. Cardiovascular safety in patients with moderate-to-severe psoriasis: Results of integrated analyses of data from phase II and III clinical studies. Br J Dermatol 2011;164:862-72.